淋巴瘤相关噬血细胞综合征的诊治新进展  

Advances in diagnosis and treatment of lymphoma-associated hemophagocytic syndrome

作　　者：樊姿影 谭获[1] Fan Ziying;Tan Huo(Department of Hematology,First Affiliated Hospital of Guangzhou Medical University,Guangzhou 510260,Guangdong Province,China)

机构地区：[1]广州医科大学附属第一医院血液科,510260

出　　处：《国际输血及血液学杂志》2020年第5期405-412,共8页International Journal of Blood Transfusion and Hematology

基　　金：国家自然科学基金(81870113)。

摘　　要：淋巴瘤相关噬血细胞综合征(LAHS)是由淋巴瘤诱导,或者在淋巴瘤化疗过程中免疫抑制引发的淋巴细胞、巨噬细胞异常增殖和活化,进而导致细胞因子过度释放,最终引起器官浸润和组织损伤的综合征。目前,国际上尚未达成LAHS的诊治标准共识。通过联合化疗诱导缓解后,行序贯造血干细胞移植(HSCT)是较为常用的LAHS治疗策略。笔者拟就LAHS的诊治最新研究进展进行阐述,旨在为LAHS的临床诊治提供参考。Lymphoma-associated hemophagocytic syndrome(LAHS)is a kind of abnormal proliferation and activation of lymphocytes and macrophages induced by lymphoma or iatrogenic immunosuppression from lymphoma chemotherapy,which results excessive release of inflammatory cytokines and eventually leads to organ infiltration and tissue damage.At present,there is no universally accepted diagnostic criteria consensus for LAHS.Induction remission of LAHS through combined chemotherapy and sequential hematopoietic stem cell transplantation(HSCT)is a common therapy.This article summarizes the latest research on diagnosis and treatment of LAHS,in order to provide a reference for the clinical diagnosis and therapy of LAHS.

关 键 词：淋巴瘤 淋巴组织细胞增多症 噬血细胞性 诊断 免疫疗法 造血干细胞移植 分子靶向治疗 淋巴瘤相关噬血细胞综合征 

分 类 号：R733.1[医药卫生—肿瘤]